Androgen-responsive POSLUMA-guided Intra-prostatic Boost

This research study is for men with intermediate- or high-risk prostate cancer who are planning to receive hormone therapy and radiation treatment. The purpose of the study is to see whether a special type of diagnostic imaging done during hormone therapy can help doctors more accurately target remaining cancer with radiation, while avoiding areas that may no longer need extra treatment. All participants will receive standard hormone therapy and radiation therapy, along with three imaging scans, over a six-month period. The information gained from this study may help make prostate cancer radiation treatment more precise and reduce side effects for future patients.

NCT Number	NCT07393867
Lead Sponsor	Martin T. King, MD, PhD Collaborators: Blue Earth Diagnostics, Dana-Farber/Brigham and Women's Cancer Center
Conditions	Intermediate Risk Prostate Cancer, High Risk Prostate Cancer, Prostate Cancer
Enrollment	23 participants
Start Date	2026-04-29
Primary Completion	2026-12-15 (estimated)
Study Completion	2027-12-15 (estimated)
Updated on ClinicalTrials.gov	2026-05-29